Plain English Summary
Background and study aims
Delirium (acute confusion) affects more than 15% of acute hospital patients. It is commonly due to acute illness, trauma or the side effects of drugs and can be very distressing for the patient and their families. Rapid detection of delirium is vital so that the patient can receive the appropriate treatment and support. Currently doctors use screening tools to help them assess whether a patient has delirium. However these are not suitable for all patients and can be time consuming to use. As a result it is estimated that two-thirds of acute hospital patients with delirium are not being diagnosed. A new quick, easy to use screening tool for delirium and cognitive impairment called the 4AT has been developed to help doctors diagnose delirium. It has 4 parts and is very quick to complete. In this study we compare the new 4AT screening tool against a reference standard assessment to show that it can be used to accurately diagnose delirium. The 4AT is compared with one of the most commonly used screening tools, the CAM (Confusion Assessment Method) to find out if it performs similarly whilst being potentially quicker to use. The study also includes a cost evaluation. The study's findings will improve the diagnosis of delirium allowing better management by the clinical team thereby improving both patient care and outcomes.
Who can participate?
Patients who are admitted to hospital via the emergency department or through acute general medical or geriatric units will be eligible. The 4AT study aims to recruit 900 patients over 70 years old from the 3 hospitals involved in the study.
What does the study involve?
Patients on the study are split into one of two groups at random. One group is screened for delirium using the 4AT screening tool while the other group is screened using the CAM screening tool. All patients on the study are screened using the reference standard assessment. Patients are screened within the first two days following admission. Information about their subsequent hospital stay will be collected from their medical records.
What are the possible benefits and risks of participating?
Patients on this study will be screened twice for delirium. There are no known risks to these assessments. A possible benefit of participation is that patients on this study in either group may be diagnosed with delirium more frequently which will mean that more can receive more appropriate care.
Where is the study run from?
The University of Edinburgh and NHS Lothian (UK)
When is study starting and how long is it expected to run for?
March 2015 to end of May 2017
Who is funding the study?
National Institute for Health Research; Health Technology Assessment Programme (UK)
Who is the main contact?
Professor Alasdair MacLullich
Prof Alasdair MacLullich
Professor of Geriatric Medicine
Edinburgh Delirium Research Group
Geriatric Medicine Unit
University of Edinburgh
Royal Infirmary of Edinburgh
51 Little France Crescent
Development and validation of the 4AT- a new rapid screening tool for delirium: a multicentre randomised controlled trial
The diagnostic screening performance of 4AT will be assessed by comparing the diagnostic accuracy of the 4AT with the reference standard (Delirium Rating Scale-Revised-98) using the positive and negative predictive values, sensitivity and specificity.
1. The 4AT will be compared with one of the most commonly used screening tools, the short CAM (Confusion Assessment Method)
2. Performance of the 4AT cognitive screening assessment will be evaluated
3. Performance of the 4AT in predicting clinical outcomes will be evaluated
More details can be found at http://www.nets.nihr.ac.uk/projects/hta/1114301
Protocol can be found at http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0009/113949/PRO-11-143-01.pdf
1. Scotland A REC, 03/07/2015, ref: 15/SS/0071
2. Yorkshire & The Humber – Bradford Leeds REC, 16/09/2015, ref: 15/YH/0317
Multicentre randomised controlled trial
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Patients on the study will be randomised into one of 2 groups. One group will be screened for delirium using the 4AT screening tool while the other group will be screened using the CAM (Confusion Assessment Method) screening tool. All patients on the study will also be screened using the reference standard assessment (Delirium Rating Scale-Revised-98). Patients will be screened within the first two days following admission. Information about their subsequent hospital stay will be collected from their medical records.
Primary outcome measures
Primary objective: 4AT vs reference standard (binary): the diagnostic screening performance of 4AT versus the reference standard will be assessed using the positive and negative predictive values, sensitivity and specificity. The exact binomial 95% confidence interval will be reported for each measure. An ROC curve will be constructed to verify that the proposed cut point on the 4AT score is appropriate. The area under the ROC curve and its 95% confidence interval will be reported.
Secondary outcome measures
1. 4AT vs short CAM: differences in each of sensitivity, specificity, positive and negative predictive values between 4AT and short CAM will be tested by Fisher's exact test and quantified by the difference in the two proportions (4AT-CAM) and its 95% confidence interval. To aid comparison of 4AT and CAM, the overall performance of each will also be summarised using Youden's Index (sensitivity minus false positive rate) and the odds ratio of sensitivity to specificity.
2. Performance of the 4AT cognitive screening items: is the 4AT an adequately sensitive tool for detecting general cognitive impairment as judged against a documented history of dementia and/or the Informant Questionnaire for Cognitive Decline in the Elderly? Methods as per primary objective.
3. 4AT vs clinical outcomes: as assessment of criterion validity, the performance of the 4AT in predicting length of stay, institutionalisation, and mortality, up to 12 weeks. Descriptive statistics of clinical outcomes (continuous variables: mean, median, standard deviation, minimum, maximum; categorical variables, number and percentage of participants) will be presented for the groups with and without 4AT scores above the cut point of 3.
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Subject > 70 years old
2. Subject admitted to hospital via:
2.1. Emergency Department (ED)
2.2. Acute general medical and geriatric unit
Target number of participants
Participant exclusion criteria
1. Acute life-threatening illness
2. Communication difficulties
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Royal Infirmary of Edinburgh Little France Edinburgh
Trial participating centre
Sheffield Teaching Hospitals NHS Foundation Trust
Weston Park Hospital Whitham Road
Trial participating centre
Bradford Teaching Hospitals NHS Foundation Trust
Bradford Royal Infirmary
University of Edinburgh and NHS Lothian - co-sponsors (UK)
c/o M. Bucukoglu
Head of Research Governance
Research and Development
The Queens Medical Research Institute
47 Little France Crescent
Health Technology Assessment Programme Ref. 11/143/01
NIHR Health Technology Assessment Programme, HTA
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
To be confirmed at a later date
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
2018 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/29440152